Cancer

News

AZ prepares for showdown with AbbVie/J&J as Calquence shines...

AstraZeneca has announced data showing its cancer drug Calquence outperformed standard care in chronic lymphocytic leukaemia – reducing risk of disease progression or death by 69%.

News

Liquid drop from laboratory glass pipette to test tube

EU safety experts begin review of leuprorelin-containing dru...

European safety experts are to begin a review of leuprorelin-containing medicines, commonly used in breast and prostate cancer and as a contraceptive.

News

Roche's blockbuster breast cancer drug Herceptin

FDA approves Herceptin biosimilar as US patent expires

The FDA has approved Amgen and Allergan’s biosimilar of Roche’s Herceptin, just in time for the breast cancer blockbuster’s patent expiry.

News

Janssen J&J Johnson and Johnson pharmaceutical companies

Janssen to develop Darzalex successor with Genmab

Janssen has signed a licence and option deal with Denmark’s Genmab to develop a next-generation drug that it hopes will outperform its already-marketed Darzalex in multiple myeloma, and oth

News

FDA approves Roche's $90,000 lymphoma combination

The FDA has quickly approved a new antibody treatment for an aggressive form of lymphoma from Roche – costing in the region of $90,000 for a four-month course.

News

AZ/Merck & Co wow ASCO with pancreatic cancer data

Finding targeted therapies for pancreatic cancer has long been an issue for pharma, meaning that for decades the only real option has been a course of chemotherapy, with unpleasant side-eff

AZ prepares for showdown with AbbVie/J&J as Calquence shines...

EU safety experts begin review of leuprorelin-containing dru...

FDA approves Herceptin biosimilar as US patent expires

Janssen to develop Darzalex successor with Genmab

FDA approves Roche's $90,000 lymphoma combination

AZ/Merck & Co wow ASCO with pancreatic cancer data

Delivering the right behavioural ingredients for the moment,...

How to meet your physicians where they are online

Cancer

Editor's Picks